Antihyperglycemic Medications and Cardiovascular Risk Reduction

Cardiovascular disease (CVD) remains a leading cause of death in patients with type 2 diabetes (T2D). In addition to glycemic control, a major focus of diabetes treatment involves cardiovascular (CV) risk reduction. In 2008, the US Food and Drug Administration (FDA) instituted a new requirement that...

Descripción completa

Detalles Bibliográficos
Autores principales: Anderson, Sarah L, Marrs, Joel C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Touch Medical Media 2017
Materias:
Cardiovascular Risk Reduction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813471/
https://www.ncbi.nlm.nih.gov/pubmed/29632614
http://dx.doi.org/10.17925/EE.2017.13.02.86

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5813471/
https://www.ncbi.nlm.nih.gov/pubmed/29632614
http://dx.doi.org/10.17925/EE.2017.13.02.86

Ejemplares similares